PURE · Pure Bioscience, Inc. · Debt
$0.09
+0.01 (+12.64%)
At close · Oct 23
Return incl. dividend (before tax)
Going-concern doubt
— flagged Jun 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our history of recurring operating losses, and negative cash flows from operating activities give rise to substantial doubt regarding our ability to continue as a going concern.”View the 10-Q filed Jun 15, 2026
Market Cap
$11.70M
Shares
130.02M
Volume · Oct 23
22.5K
Avg daily vol (3M)
31.87K
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Notes payable, including current maturities | 2026-04-30 | USD 6,497,000 | 10-Q filed 2026-06-15 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.